MedTrace Logo

Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children

NCT00031395 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2009-05-21

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of clonidine alone or in combination with methylphenidate for children 7-12 years of age with attention-deficit, hyperactivity disorder.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

clonidine

Clonidine is FDA-approved for the treatment of hypertension in adults.

DRUG

methylphenidate

MPH is FDA-approved for the treatment of ADHD symptoms in children.

OTHER

placebo

an inactive substance

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Floyd R. Sallee, M.D., Ph.D. · Children's Hospital & Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00031395 on ClinicalTrials.gov